CHeT Analytics is developing strategies to reduce drug development costs and enhance clinical care for those living with neurodegenerative diseases. By leveraging one of the world’s largest repositories of clinical trial data for Parkinson’s and Huntington’s diseases, new insights are being made possible through predictive modeling and simulation.
With access to clinical trial and observational study data from over 100 studies and extensive knowledge of developing neurodegenerative disease progression models, our capabilities of modeling novel clinical design enrichment strategies
- Reduce trial sample size
- Truncate trial follow-up times
- Decrease drug development costs
The Analytics Unit is developing tools for patients, clinicians, and caregivers to interact with the prediction models to help manage their disease in a data-driven manner. We believe creating such tools empowers patients and allows the entire care team to proactively plan for future scenarios that are based on real patients’ data of similar profiles.
We specialize in drug development rescue re-analysis. Our modeling and simulation methods are able to identify sub-populations of treatment responders and exposure-response relationships, if any such exist, through post-hoc analyses. Let us help you make the most of the data you have collected.